A Look at Sichuan Kelun-Biotech (SEHK:6990) Valuation After New Sacituzumab Tirumotecan Clinical Data Revealed

Simply Wall St.
Nov 11

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) drew attention at the 2025 Chinese Congress on Holistic Integrative Oncology with presentations on sacituzumab tirumotecan, its TROP2 ADC therapy. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10